Search Results

You are looking at 1 - 10 of 1,027 items for :

  • Refine by Access: All x
Clear All
Full access

David Y. T. Chen and Robert G. Uzzo

Edited by Kerrin G. Robinson

. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients . Ann Surg 1999 ; 230 : 1 – 8 . 30 Dupuy DE Zagoria RJ Akerley W . Percutaneous radiofrequency ablation of malignancies in the lung . AJR

Full access

Cletus A. Arciero and Elin R. Sigurdson

comparison of radio-frequency thermal ablation versus percutaneous ethanol injection . Radiology 2003 ; 228 : 235 – 240 . 36. Livraghi T Bolondi L Lazzaroni S . Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in

Full access

Michel Kahaleh

Endoscopic Biliary Drainage “From an endoscopy standpoint, knowing the different segments of the liver is crucial in terms of being able to provide biliary decompression,” declared Dr. Kahaleh. “Everything we do is based on symptoms and imaging,” he added

Full access

Adrian Legaspi, Vanitha Vasudevan, Amit Sastry, and Jeronimo Garcialopez de Llano

laparoscopic, ultrasound-guided microwave ablation (LMA) for the management of primary and metastatic malignancy to the liver alone or in combination with additional loco-regional therapy (Y-90 radioembolization) and/or systemic chemotherapy or immunotherapy

Full access

Thomas B. Nealis, Kay Washington, and Rajesh N. Keswani

's esophagus cases to reduce the risk of synchronous or metachronous lesions. Complete remission ranges from 94% to 97% for patients undergoing CBE-EMR for HGD or intramucosal adenocarcinoma, with focal radiofrequency ablation used in some cases. 54 However

Full access

Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey

use in premenopausal women, there are long-term risks of ovarian ablation (OA), which is a necessary additional intervention in women who still have ovarian function. A recent study found that OA preceeding an AI (OA/AI) was more costly and less

Full access

En Cheng, Peiyin Hung, and Shi-Yi Wang

Evidence-based HCC management guidelines have been updated to take full advantage of current treatment options, including transplantation, surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), transarterial

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

Tamoxifen for Longer Against Shorter (ATLAS) Trial is comparing 5 to 10 years, and the Adjuvant Tamoxifen Treatment Offer More (ATTOM) trial is comparing 5 years with various longer durations. Ovarian Ablation or Suppression in the Premenopausal Setting The

Full access

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy, and Jaffer A. Ajani

, preferably, endoscopic mucosal resection (EMR) biopsy of the lesion to evaluate for submucosal extension. For patients with a T1aN0M0 tumor, treatment options include EMR with negative pathologic margins and ablation of at-risk adjacent mucosa or

Full access

Joseph M. Herman, John P. Hoffman, Sarah P. Thayer, and Robert A. Wolff

. Fourth, image-guided percutaneous radiofrequency ablation (RFA) and laparoscopically assisted RFA may allow for management of limited metastatic disease and spare patients the toxicity associated with ongoing cytotoxic chemotherapy. Lastly, the